Daily PulseNews

Experimental Drug Combination Achieves Substantial Tumor Shrinkage in Advanced Pancreatic Cancer

Early clinical trial results reveal that an investigational oral medication, when combined with chemotherapy, effectively shrank tumors or halted disease progression in a majority of patients with metastatic pancreatic cancer.

November 21, 2026 · Health

Experimental Drug Combination Achieves Substantial Tumor Shrinkage in Advanced Pancreatic Cancer

An experimental oral medication, when administered alongside conventional chemotherapy, has shown the ability to shrink tumors or stop their growth in a majority of patients suffering from advanced pancreatic cancer. These promising preliminary findings emerged from a phase 1/2 clinical trial presented recently at the EORTC-NCI-AACR Symposium in Barcelona. The regimen involved a daily oral dose of daraxonrasib, an investigational drug, in combination with two established intravenous chemotherapy agents: gemcitabine and nab-paclitaxel.

The study specifically enrolled 61 participants whose pancreatic cancer had metastasized to other parts of the body and who had not yet received treatment for their advanced stage disease.

Pancreatic cancer is notoriously challenging to treat, primarily because a significant proportion—over half—of diagnoses occur after the disease has already spread. Research indicates that for metastatic pancreatic cancer, chemotherapy alone typically results in tumor shrinkage for approximately 23% to 42% of patients. However, disease progression often resumes within five to six months, and the median survival for most patients ranges from 8 to 11 months. Data from the National Cancer Institute further highlights the severity, reporting that only about 3% of individuals with distant-stage pancreatic cancer survive five years post-diagnosis.

Significant Clinical Responses Observed

In the current study, which followed patients for a median of 18 months, tumors visibly shrank in 60.7% of participants. Notably, in 8.2% of these cases, scans revealed a complete disappearance of the tumors. Overall, the investigational combination therapy successfully halted tumor growth in 90.2% of the individuals treated.

Patients on the new regimen experienced a median of 12.8 months before their cancer began to worsen, nearly doubling the typical timeframe observed with standard chemotherapy. Furthermore, the study reported that 76.6% of participants were still alive at the one-year mark.

Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York and the lead author of the study, commented in a press release on the encouraging results. He stated,

We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year.

Targeting a Key Genetic Driver

More than 90% of pancreatic cancers are characterized by a mutation in the RAS gene, a defect that continuously signals tumor cells to grow. Daraxonrasib is specifically engineered to deactivate this growth signal, addressing a biological pathway that scientists previously considered extremely difficult to target effectively with medication.

Dr. Elena Garralda, who chairs the symposium and co-directs the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, offered an independent perspective on the findings. Not involved in this particular research, Dr. Garralda noted that the results demonstrate the potential for RAS-targeted drugs to be integrated with existing treatments early in the therapeutic process, potentially leading to more sustained benefits for patients.

Managing Side Effects and Future Directions

Reported side effects included skin rash, diarrhea, fatigue, and reduced blood cell counts, which are commonly associated with chemotherapy. Most of these effects were manageable through standard medical care. A small percentage, only 5% of patients, discontinued treatment due to side effects specifically attributed to daraxonrasib.

The researchers acknowledged certain limitations within the findings. As an early-phase, single-group study involving 61 participants, all received the experimental combination. The absence of a direct control group, receiving only standard chemotherapy, means that a definitive confirmation of the new regimen's superior performance or its ability to extend overall survival cannot yet be made. Additionally, these findings are strictly applicable to metastatic pancreatic cancer. While RAS mutations are implicated in several other cancer types, including certain lung, colorectal, and gynecological cancers, separate investigations would be necessary to determine the efficacy of this combination in those diseases.

The trial received funding from Revolution Medicines, the California-based company responsible for developing daraxonrasib. To ascertain whether these initial positive outcomes translate into a lasting survival advantage, a larger, randomized Phase 3 trial, designated RASolute-303, has been initiated. This upcoming study will directly compare daraxonrasib—both as a standalone therapy and in combination with chemotherapy—against standard chemotherapy alone.

pancreatic cancer treatmentdaraxonrasibadvanced cancertumor shrinkagechemotherapy combinationRAS gene mutationcancer clinical trialmetastatic pancreatic cancer